[go: up one dir, main page]

WO2012105798A3 - 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물 - Google Patents

클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2012105798A3
WO2012105798A3 PCT/KR2012/000746 KR2012000746W WO2012105798A3 WO 2012105798 A3 WO2012105798 A3 WO 2012105798A3 KR 2012000746 W KR2012000746 W KR 2012000746W WO 2012105798 A3 WO2012105798 A3 WO 2012105798A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
chlorogenic acid
treating gastroesophageal
reflux disease
gastroesophageal reflux
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/000746
Other languages
English (en)
French (fr)
Other versions
WO2012105798A2 (ko
Inventor
이선미
강정우
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sungkyunkwan University Foundation for Corporate Collaboration
Original Assignee
Sungkyunkwan University Foundation for Corporate Collaboration
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sungkyunkwan University Foundation for Corporate Collaboration filed Critical Sungkyunkwan University Foundation for Corporate Collaboration
Publication of WO2012105798A2 publication Critical patent/WO2012105798A2/ko
Publication of WO2012105798A3 publication Critical patent/WO2012105798A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 클로로겐산(chlorogenic acid), 이의 약학적으로 허용가능한 염, 또는 이의 유도체를 포함하는, 위식도 역류 질환의 예방 또는 치료용 약학적 조성 물 및 위식도 역류 질환의 예방 또는 개선용 식품 조성물, 상기 약학적 조성물을 개체에 투여하는 단계를 포함하는 위식도 역류 질환을 예방 또는 치료하는 방법, 및 클로로겐산, 이의 약학적으로 허용가능한 염, 또는 이의 유도체의 용도에 관한 것이다. 본 발명에 따르면, 클로로겐산, 이의 약학적으로 허용가능한 염, 또는 이의 유도체는 위 내 pH 변화 없이, 위 또는 십이지장의 내용물이 식도로 역류하여 발생되는 식도 병변의 면적을 감소시키고, 염증 세포의 조직학적 변화를 감소시키는 바, 부작용 없이 위식도 염류성 질환의 예방 또는 치료에 유용하게 사용될 수 있다.
PCT/KR2012/000746 2011-01-31 2012-01-31 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물 Ceased WO2012105798A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110009729 2011-01-31
KR10-2011-0009729 2011-01-31

Publications (2)

Publication Number Publication Date
WO2012105798A2 WO2012105798A2 (ko) 2012-08-09
WO2012105798A3 true WO2012105798A3 (ko) 2012-12-20

Family

ID=46603207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000746 Ceased WO2012105798A2 (ko) 2011-01-31 2012-01-31 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물

Country Status (2)

Country Link
KR (1) KR101420347B1 (ko)
WO (1) WO2012105798A2 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101074839B1 (ko) * 2010-11-25 2011-10-19 주식회사 녹십자 금은화 추출물을 포함하는 역류성 식도염 치료 또는 예방용 약학조성물
BR112015005921A2 (pt) * 2012-09-21 2017-07-04 Nestec Sa fenóis da planta e seu uso no tratamento ou prevenção de esofagite eosinofílica
KR102157795B1 (ko) 2018-12-06 2020-09-18 (주)녹십자웰빙 금은화 물 추출물을 포함하는 헬리코박터 파일로리 감염증 예방 또는 치료용 약학 조성물
KR102332846B1 (ko) * 2019-09-06 2021-11-30 고려대학교 산학협력단 과식에 의해 유도된 위식도역류질환 동물모델의 제조방법
CN118401118A (zh) * 2021-12-17 2024-07-26 嘉吉公司 用于减糖可可组合物的感官改性剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100878436B1 (ko) * 2008-08-18 2009-01-13 주식회사 지씨에이치앤피 금은화 추출물을 포함하는 소화성 궤양 치료 또는 예방용 약학조성물
KR20100043882A (ko) * 2008-10-21 2010-04-29 김정환 헬리코박터 파이로리 균에 항균능을 갖는 뽕잎추출물, 이의제조방법 및 이를 이용한 건강기능식품
WO2010083968A1 (en) * 2009-01-20 2010-07-29 Indena S.P.A. Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
KR101074839B1 (ko) * 2010-11-25 2011-10-19 주식회사 녹십자 금은화 추출물을 포함하는 역류성 식도염 치료 또는 예방용 약학조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100878436B1 (ko) * 2008-08-18 2009-01-13 주식회사 지씨에이치앤피 금은화 추출물을 포함하는 소화성 궤양 치료 또는 예방용 약학조성물
KR20100043882A (ko) * 2008-10-21 2010-04-29 김정환 헬리코박터 파이로리 균에 항균능을 갖는 뽕잎추출물, 이의제조방법 및 이를 이용한 건강기능식품
WO2010083968A1 (en) * 2009-01-20 2010-07-29 Indena S.P.A. Compositions comprising a lipophilic extract of zingiber officinale and an extract of cynara scolymus, which are useful for the prevention and treatment of oesophageal reflux and irritable bowel syndrome
KR101074839B1 (ko) * 2010-11-25 2011-10-19 주식회사 녹십자 금은화 추출물을 포함하는 역류성 식도염 치료 또는 예방용 약학조성물

Also Published As

Publication number Publication date
KR101420347B1 (ko) 2014-07-16
WO2012105798A2 (ko) 2012-08-09
KR20120088610A (ko) 2012-08-08

Similar Documents

Publication Publication Date Title
WO2012094598A3 (en) Pharmaceutical compositions of iron for oral administration
EA201490852A1 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
WO2012031124A3 (en) Drug formulations using water soluble antioxidants
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
WO2012105798A3 (ko) 클로로겐산을 포함하는 위식도 역류 질환의 예방 또는 치료용 조성물
EA201490014A1 (ru) Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот
SI3683209T1 (sl) Postopek za pripravo ((5-(3-klorofenil)-3-hidroksipiridin-2-karbonil)-amino)ocetne kisline iz 5-((3-klorofenil)-3-kloro-piridin-2-il)-nitrila in postopek za pripravo derivatov 5-((halofenil)-3-halo-piridin-2-il)-nitrila
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
WO2009062118A3 (en) Modulation of protein trafficking
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
WO2012106303A1 (en) Pharmaceutical formulations including an amine compound
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2009094560A3 (en) Thienopyranones as kinase inhibitors
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
DK2268605T3 (da) Fedtsyrederivater til oral indgivelse forsynet med høj palatabilitet
WO2009095624A3 (fr) Procede de preparation d'acides dicafeoylquiniques et leur utilisation dans la lutte contre les pucerons
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
WO2010114425A3 (ru) Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12- перстной кишки
WO2012064396A3 (en) Novel ezrin inhibitors and methods of making and using
NZ624708A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
WO2007095117A3 (en) Method for improving the oral administration of alpha-lipoic acid
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
JP2014532758A5 (ko)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12742368

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12742368

Country of ref document: EP

Kind code of ref document: A2